Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Front Cardiovasc Med ; 9: 832098, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35433851

RESUMO

Background: Takotsubo syndrome is an acute cardiac condition involving sudden, transient apical ballooning of the left ventricle of the heart that may be triggered by emotional stress and some non-cardiac conditions. Its diagnosis is based on clinical presentation, electrocardiogram, cardiac imaging and biomarkers. Case Summary: Here, we present a novel and original case report of a patient presenting very soon in the post-partum period with an unusual form of Takotsubo syndrome without clinical symptoms of cardiac disease and accompanied by HELLP syndrome. The overall dynamics of the changes in troponin I, troponin T and NT-proBNP levels after delivery were generally similar, but the amount of troponin I was much greater than that of troponin T and troponin I was already elevated before delivery. NT-proBNP levels peaked around the same time as the troponins and the peak concentration was within the same range as that of troponin I. Discussion: Our findings indicate that assaying circulating cardiac biomarkers, especially troponin I and NT-proBNP, may be a useful complement to non-invasive cardiac imaging including transthoracic echocardiography and cardiovascular magnetic resonance imaging, in the diagnosis of Takotsubo syndrome. They illustrate the importance of cardiac biomarkers in assisting diagnosis of this disease.

2.
PLoS One ; 16(4): e0250728, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33914786

RESUMO

Among 197 COVID-19 patients hospitalized in ICU, 88 (44.7%) experienced at least one bacterial infection, with pneumonia (39.1%) and bloodstream infections (15,7%) being the most frequent. Unusual findings include frequent suspicion of bacterial translocations originating from the digestive tract as well as bacterial persistence in the lungs despite adequate therapy.


Assuntos
Infecções Bacterianas/complicações , COVID-19/complicações , Pneumonia Bacteriana/complicações , Idoso , Infecções Bacterianas/epidemiologia , COVID-19/epidemiologia , Feminino , França/epidemiologia , Hospitalização , Humanos , Unidades de Terapia Intensiva , Pulmão/microbiologia , Pulmão/virologia , Masculino , Pessoa de Meia-Idade , Pneumonia Bacteriana/epidemiologia
3.
Eur J Clin Microbiol Infect Dis ; 40(10): 2227-2234, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33733394

RESUMO

Because the diagnosis of co/superinfection in COVID-19 patients is challenging, empirical antibiotic therapy is frequently initiated until microbiological analysis results. We evaluated the performance and the impact of the BioFire® FilmArray® Pneumonia plus Panel on 112 respiratory samples from 67 COVID-19 ICU patients suspected of co/superinfections. Globally, the sensitivity and specificity of the test were 89.3% and 99.1%, respectively. Positive tests led to antibiotic initiation or adaptation in 15% of episodes and de-escalation in 4%. When negative, 28% of episodes remained antibiotic-free (14% no initiation, 14% withdrawal). Rapid multiplex PCRs can help to improve antibiotic stewardship by administering appropriate antibiotics earlier and avoiding unnecessary prescriptions.


Assuntos
Antibacterianos/uso terapêutico , Bactérias/isolamento & purificação , Infecções Bacterianas/tratamento farmacológico , COVID-19/complicações , Reação em Cadeia da Polimerase Multiplex/métodos , Idoso , Gestão de Antimicrobianos , Bactérias/classificação , Bactérias/efeitos dos fármacos , Bactérias/genética , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/microbiologia , COVID-19/virologia , Feminino , Hospitalização , Humanos , Unidades de Terapia Intensiva/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , SARS-CoV-2/genética , SARS-CoV-2/fisiologia
4.
Can J Hosp Pharm ; 72(1): 7-15, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30828089

RESUMO

BACKGROUND: Drug shortages represent a complex global problem affecting patients and health care professionals on a daily basis. OBJECTIVES: To identify, describe, and compare drug shortages in health care facilities in Canada and 4 European countries in early 2018. METHODS: A descriptive cross-sectional study was conducted in 1 hospital in each of 5 countries: Canada, France, Belgium, Spain, and Switzerland. Over a 4-week period, shortage data were collected daily by each hospital using a standardized grid and a standard process. RESULTS: From January 8 to February 2, 2018, there were a total of 84 shortages (median duration 32 days) in the Canadian hospital, 62 shortages (median duration 9 days) in the French hospital, 46 shortages (median duration 37 days) in the Belgian hospital, 28 shortages (median duration 25 days) in the Spanish hospital, and 98 shortages (median duration 68 days) in the Swiss hospital. The number of manufacturers implicated in the shortages was 28 for the Canadian hospital, 30 for the French hospital, 19 for the Belgian hospital, 16 for the Spanish hospital, and 42 for the Swiss hospital. Most of the shortages involved parenteral drugs, with both innovative and generic manufacturers being affected. Most therapeutic classes were affected by shortages to some extent, with the top 3 classes being anti-infective agents (accounting for 21.1% of shortages overall), central nervous system drugs (11.3%), and cardiovascular drugs (8.2%). CONCLUSIONS: Drug shortages occurred almost daily in all of the study hospitals. Across the 5 hospitals, the frequency of shortages varied by a factor of 3, which may imply similar variability at the national level. All stakeholders should work more diligently to prevent and manage drug shortages.


CONTEXTE: Les pénuries de médicaments représentent un problème mondial complexe qui touche quotidiennement les patients et les professionnels de la santé. OBJECTIFS: Recenser, décrire et comparer les pénuries de médicaments ayant eu lieu au début de 2018 dans des établissements de soins de santé du Canada et de quatre pays d'Europe. MÉTHODES: Une étude descriptive et transversale a été menée dans un hôpital de chacun des cinq pays suivants: le Canada, la France, la Belgique, l'Espagne et la Suisse. Sur une période de quatre semaines, chaque hôpital a recueilli quotidiennement les données sur les pénuries à l'aide d'une grille et d'un processus normalisés. RÉSULTATS: Pour la période allant du 8 janvier au 2 février 2018, on a recensé 84 pénuries (durée médiane de 32 jours) dans l'hôpital canadien, 62 pénuries (durée médiane de 9 jours) dans l'hôpital français, 46 pénuries (durée médiane de 37 jours) dans l'hôpital belge, 28 pénuries (durée médiane de 25 jours) dans l'hôpital espagnol et 98 pénuries (durée médiane de 68 jours) dans l'hôpital suisse. Vingt-huit (28) fabricants étaient impliqués dans les cas de pénuries dans l'hôpital canadien, 30 dans l'hôpital français, 19 dans l'hôpital belge, 16 dans l'hôpital espagnol et 42 dans l'hôpital suisse. La plupart des pénuries touchaient les médicaments parentéraux et mettaient en cause tant les fabricants de médicaments novateurs que ceux de médicaments génériques. Les pénuries ont affecté d'une manière ou d'une autre la plupart des classes de médicaments, mais les trois classes les plus touchées étaient les agents anti-infectieux (21,1 %) les médicaments agissant sur le système nerveux central (11,3 %) et les agents cardiovasculaires (8,2 %). CONCLUSIONS: Des pénuries survenaient presque quotidiennement dans chaque hôpital de l'étude. Dans l'ensemble des hôpitaux, la fréquence des pénuries variait selon un facteur de trois, ce qui pourrait se traduire par une variabilité semblable à l'échelle nationale. Toutes les parties prenantes doivent travailler avec plus d'ardeur à la prévention et à la gestion des pénuries de médicaments.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA